Nanotechnology in cancer therapy: Targeting the inhibition of key DNA repair pathways

Aziz, K; Nowsheen, S; Georgakilas, AG

dc.contributor.author	Aziz, K	en
dc.contributor.author	Nowsheen, S	en
dc.contributor.author	Georgakilas, AG	en
dc.date.accessioned	2014-03-01T01:33:49Z
dc.date.available	2014-03-01T01:33:49Z
dc.date.issued	2010	en
dc.identifier.issn	1566-5240	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/20607
dc.subject	Base excision repair	en
dc.subject	Cancer therapy	en
dc.subject	DNA damage	en
dc.subject	DNA repair	en
dc.subject	Double strand break repair	en
dc.subject	Inhibitors	en
dc.subject	Nanotechnology	en
dc.subject.classification	Medicine, Research & Experimental	en
dc.subject.other	2 (2 methyl 2 pyrrolidinyl) 1h benzimidazole 4 carboxamide	en
dc.subject.other	5 aza 2' deoxycytidine	en
dc.subject.other	antineoplastic agent	en
dc.subject.other	bsi 201	en
dc.subject.other	captopril	en
dc.subject.other	carboplatin	en
dc.subject.other	cetuximab	en
dc.subject.other	cisplatin	en
dc.subject.other	gemcitabine	en
dc.subject.other	irinotecan	en
dc.subject.other	lithium	en
dc.subject.other	olaparib	en
dc.subject.other	pemetrexed	en
dc.subject.other	temozolomide	en
dc.subject.other	trc 102	en
dc.subject.other	unclassified drug	en
dc.subject.other	article	en
dc.subject.other	brain tumor	en
dc.subject.other	breast cancer	en
dc.subject.other	cancer genetics	en
dc.subject.other	cancer therapy	en
dc.subject.other	carcinogenesis	en
dc.subject.other	colorectal cancer	en
dc.subject.other	DNA damage	en
dc.subject.other	DNA repair	en
dc.subject.other	DNA strand breakage	en
dc.subject.other	drug efficacy	en
dc.subject.other	drug safety	en
dc.subject.other	excision repair	en
dc.subject.other	gene mutation	en
dc.subject.other	gene sequence	en
dc.subject.other	gene targeting	en
dc.subject.other	genetic association	en
dc.subject.other	genetic disorder	en
dc.subject.other	genetic predisposition	en
dc.subject.other	glioblastoma	en
dc.subject.other	human	en
dc.subject.other	intestine cancer	en
dc.subject.other	leukemia	en
dc.subject.other	lung cancer	en
dc.subject.other	lymphoma	en
dc.subject.other	melanoma	en
dc.subject.other	nanotechnology	en
dc.subject.other	ovary cancer	en
dc.subject.other	pharmacodynamics	en
dc.subject.other	solid tumor	en
dc.subject.other	urogenital tract tumor	en
dc.subject.other	Antineoplastic Agents	en
dc.subject.other	DNA Damage	en
dc.subject.other	DNA Repair	en
dc.subject.other	DNA Repair Enzymes	en
dc.subject.other	Drug Design	en
dc.subject.other	Enzyme Inhibitors	en
dc.subject.other	Molecular Targeted Therapy	en
dc.subject.other	Nanomedicine	en
dc.subject.other	Neoplasms	en
dc.subject.other	Poly(ADP-ribose) Polymerases	en
dc.subject.other	Radiation, Ionizing	en
dc.subject.other	Radiation, Nonionizing	en
dc.subject.other	Reactive Nitrogen Species	en
dc.subject.other	Reactive Oxygen Species	en
dc.title	Nanotechnology in cancer therapy: Targeting the inhibition of key DNA repair pathways	en
heal.type	journalArticle	en
heal.identifier.primary	10.2174/156652410792630599	en
heal.identifier.secondary	http://dx.doi.org/10.2174/156652410792630599	en
heal.language	English	en
heal.publicationDate	2010	en
heal.abstract	Cancer therapy has been changing over the decades as we move away from the administration of broad spectrum cytotoxic drugs and towards the use of therapy targeted for each tumor type. After the induction of DNA damage through chemotherapeutic agents, tumor cells can survive due to their proficient DNA repair pathways, some of which are dysregulated in cancer. Latest improvements in nanotechnology and drug discovery have led to the discovery of some very unique, highly specific and innovative drugs as inhibitors of various DNA repair pathways like base excision repair and double strand break repair. In this review we look at the efficacy and potency of these small chemical molecules to target the processing of DNA damage induced by standard therapeutic agents. Emphasis is given to those drugs currently under clinical trials. We also discuss the future directions of using this nanotechnology to increase the therapeutic ratio in cancer treatment. © 2010 Bentham Science Publishers Ltd.	en
heal.publisher	BENTHAM SCIENCE PUBL LTD	en
heal.journalName	Current Molecular Medicine	en
dc.identifier.doi	10.2174/156652410792630599	en
dc.identifier.isi	ISI:000284622700002	en
dc.identifier.volume	10	en
dc.identifier.issue	7	en
dc.identifier.spage	626	en
dc.identifier.epage	639	en